Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 1/2014

01-01-2014 | Original Article

Quantitative assessment of global hepatic glycolysis in patients with cirrhosis and normal controls using 18F-FDG-PET/CT: a pilot study

Authors: Ana Hernandez-Martinez, Victor A. Marin-Oyaga, Ali Salavati, Babak Saboury, Ion Codreanu, Marnix G. E. H. Lam, Drew A. Torigian, Abass Alavi

Published in: Annals of Nuclear Medicine | Issue 1/2014

Login to get access

Abstract

Objective

To compare differences in global measures of hepatic metabolism between control subjects and subjects with cirrhosis.

Materials and methods

FDG-PET/CT scans of 33 subjects either without or with cirrhosis were analyzed retrospectively and classified as follows: group 1 includes subjects without cirrhosis or extrahepatic malignancy (1a) (n = 11) and subjects without cirrhosis but with history of extrahepatic malignancy (1b) (n = 10); group 2 includes subjects with cirrhosis and history of extrahepatic malignancy (n = 12). Subjects with focal hepatic lesions, prior hepatic surgery, co-existing liver pathology, or who received chemotherapy or radiation therapy within the last 6 months were excluded. The hepatic volumes, hepatic mean standardized uptake value (SUVmean), and global hepatic glycolysis (GHG) were compared between groups.

Results

Subjects with cirrhosis showed a lower average hepatic SUVmean as compared to non-cirrhotic patients (1.55 ± 0.29 for group 2 versus 1.81 ± 0.23 for group 1; p value = 0.009) and lower average values for GHG (2238.29 ± 903.60 for group 2 versus 2974.67 ± 829.16 for group 1; p value = 0.024). No differences were noted between the non-cirrhotic subgroups (i.e., between the groups 1a and 1b) without and with associated extrahepatic malignancy, respectively.

Conclusions

We hypothesize that presence of fibrosis, reduction of active inflammation, and decreased hepatic metabolism and function are potential causes of the lower FDG uptake in cirrhotic livers. Our results also indicate that extrahepatic cancer status does not influence FDG uptake in the non-cirrhotic liver in subjects without hepatic metastases.
Literature
1.
Hansen L, Sasaki A, Zucker B. End-stage liver disease: challenges and practice implications. Nurs Clin North Am. 2010;45(3):411–26.PubMedCrossRef
2.
3.
Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, et al. Does this patient with liver disease have cirrhosis? JAMA. 2012;307(8):832–42.PubMedCrossRef
4.
Riley TR, Taheri M, Schreibman IR. Does weight history affect fibrosis in the setting of chronic liver disease? J Gastrointestin Liver Dis. 2009;18(3):299–302.PubMed
5.
Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124(11):1599–607.PubMed
6.
Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol. 2004;40(5):860–7.PubMedCrossRef
7.
de Graaf W, Bennink RJ, Vetelainen R, van Gulik TM. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med. 2010;51(5):742–52.PubMedCrossRef
8.
Fierbinteanu-Braticevici C, Purcarea M. Non-biopsy methods to determine hepatic fibrosis. J Med Life. 2009;2(4):401–6.PubMedCentralPubMed
9.
Wang Y, Ganger DR, Levitsky J, Sternick LA, McCarthy RJ, Chen ZE, et al. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol. 2011;196(3):553–61.PubMedCentralPubMedCrossRef
10.
Sohail S. Hepatic fibrosis imaging: trends and feasibility. J Coll Physicians Surg Pak. 2012;22(2):73–4.PubMed
11.
Brancatelli G, Baron RL, Federle MP, Sparacia G, Pealer K. Focal confluent fibrosis in cirrhotic liver: natural history studied with serial CT. AJR Am J Roentgenol. 2009;192(5):1341–7.PubMedCrossRef
12.
Lenhart M, Feuerbach S. Role of computed tomography and magnetic resonance imaging in the diagnosis of hepatitis and liver cirrhosis. Praxis (Bern 1994). 2005;94(16):635–8.CrossRef
13.
Yoshida M, Shiraishi S, Sakaguchi F, Utsunomiya D, Tashiro K, Tomiguchi S, et al. A quantitative index measured on (9)(9)mTc GSA SPECT/CT 3D fused images to evaluate severe fibrosis in patients with chronic liver disease. Jpn J Radiol. 2012;30(5):435–41.PubMedCrossRef
14.
Yoshida M, Shiraishi S, Sakaguchi F, Utsunomiya D, Tashiro K, Tomiguchi S, et al. Fused 99m-Tc-GSA SPECT/CT imaging for the preoperative evaluation of postoperative liver function: can the liver uptake index predict postoperative hepatic functional reserve? Jpn J Radiol. 2012;30(3):255–62.PubMedCrossRef
15.
Kwon AH, Matsui Y, Ha-Kawa SK, Kamiyama Y. Functional hepatic volume measured by technetium-99m-galactosyl-human serum albumin liver scintigraphy: comparison between hepatocyte volume and liver volume by computed tomography. Am J Gastroenterol. 2001;96(2):541–6.PubMedCrossRef
16.
Onodera Y, Takahashi K, Togashi T, Sugai Y, Tamaki N, Miyasaka K. Clinical assessment of hepatic functional reserve using 99mTc DTPA galactosyl human serum albumin SPECT to prognosticate chronic hepatic diseases—validation of the use of SPECT and a new indicator. Ann Nucl Med. 2003;17(3):181–8.PubMedCrossRef
17.
Kaibori M, Ha-Kawa SK, Maehara M, Ishizaki M, Matsui K, Sawada S, et al. Usefulness of Tc-99m-GSA scintigraphy for liver surgery. Ann Nucl Med. 2011;25(9):593–602.PubMedCrossRef
18.
Alavi A, Kung JW, Zhuang H. Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med. 2004;34(1):56–69.PubMedCrossRef
19.
20.
21.
Kuker RA, Mesoloras G, Gulec SA. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol. 2007;4:17.PubMedCentralPubMedCrossRef
22.
Lin CY, Ding HJ, Lin CC, Chen CC, Sun SS, Kao CH. Impact of age on FDG uptake in the liver on PET scan. Clin Imaging. 2010;34(5):348–50.PubMedCrossRef
23.
Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer’s disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med. 1993;34(10):1681–7.PubMed
24.
Abdulla S, Salavati A, Saboury B, Basu S, Torigian DA, Alavi A. Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study. Eur J Nucl Med Mol Imaging. 2013. doi:10.​1007/​s00259-013-2579-4.
25.
Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53(12):1829–35. doi:10.​2967/​jnumed.​112.​106500.PubMedCrossRef
26.
27.
Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun. 2008;29(6):521–6. doi:10.​1097/​MNM.​0b013e3282f813a4​.PubMedCrossRef
28.
29.
Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(1):27–38. doi:10.​1007/​s00259-011-1934-6.PubMedCrossRef
30.
Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48(9):1449–58. doi:10.​2967/​jnumed.​107.​042333.PubMedCrossRef
31.
Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53(5):709–15. doi:10.​2967/​jnumed.​111.​099531.PubMedCrossRef
32.
Basu S, Zaidi H, Houseni M, Bural G, Udupa J, Acton P, et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med. 2007;37(3):223–39.PubMedCrossRef
33.
Bural GG, Torigian DA, Burke A, Houseni M, Alkhawaldeh K, Cucchiara A, et al. Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept. Mol Imaging Biol. 2010;12(3):233–9.PubMedCrossRef
34.
Abele JT, Fung CI. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology. 2010;254(3):917–24.PubMedCrossRef
35.
Dostbil Z, Varoglu E, Serdengecti M, Kaya B, Onder H, Sari O. Evaluation of hepatic metabolic activity in non-alcoholic fatty livers on (18)FDG PET/CT. Rev Esp Med Nucl Imagen Mol. 2013;32(3):156–61. doi:10.​1016/​j.​remn.​2012.​04.​006.PubMed
36.
Geraghty EM, Boone JM, McGahan JP, Jain K. Normal organ volume assessment from abdominal CT. Abdom Imaging. 2004;29(4):482–90.PubMedCrossRef
37.
Kamimura K, Nagamachi S, Wakamatsu H, Higashi R, Ogita M, Ueno S, et al. Associations between liver (18)F fluoro-2-deoxy-d-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome. Ann Nucl Med. 2010;24(3):157–61. doi:10.​1007/​s12149-009-0338-1.PubMedCrossRef
38.
Meier JM, Alavi A, Iruvuri S, Alzeair S, Parker R, Houseni M, et al. Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Semin Nucl Med. 2007;37(3):154–72.PubMedCrossRef
39.
Bural GG, Torigian DA, Chen W, Houseni M, Basu S, Alavi A. Increased 18F-FDG uptake within the reticuloendothelial system in patients with active lung cancer on PET imaging may indicate activation of the systemic immune response. Hell J Nucl Med. 2010;13(1):23–5.PubMed
40.
41.
42.
43.
Sorensen M, Mikkelsen KS, Frisch K, Villadsen GE, Keiding S. Regional metabolic liver function measured by 2-[(18)F]fluoro-2-deoxy-d-galactose PET/CT in patients with cirrhosis. J Hepatol. 2013; 8278(13). doi: 10.​1016/​j.​jhep.​2013.​01.​012.
44.
Chopra A. 18F-labeled neogalactosylalbumin. Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information (US); 2009. pp. 2004–13.
45.
Slimani L, Kudomi N, Oikonen V, Jarvisalo M, Kiss J, Naum A, et al. Quantification of liver perfusion with [(15)O]H(2)O-PET and its relationship with glucose metabolism and substrate levels. J Hepatol. 2008;48(6):974–82.PubMedCrossRef
46.
Nishiguchi S, Shiomi S, Kawamura E, Ishizu H, Habu D, Torii K, et al. Evaluation of ammonia metabolism in the skeletal muscles of patients with cirrhosis using N-13 ammonia PET. Ann Nucl Med. 2003;17(5):417–9.PubMedCrossRef
47.
Dam G, Keiding S, Munk OL, Ott P, Buhl M, Vilstrup H, et al. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2011;301(2):G269–77.PubMedCrossRef
48.
Matusch A, Meyer PT, Bier D, Holschbach MH, Woitalla D, Elmenhorst D, et al. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl Med Biol. 2006;33(7):891–8.PubMedCrossRef
49.
Sorensen M, Mikkelsen KS, Frisch K, Bass L, Bibby BM, Keiding S. Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-d-galactose PET/CT. J Nucl Med. 2011;52(10):1566–72.PubMedCentralPubMedCrossRef
Metadata
Title
Quantitative assessment of global hepatic glycolysis in patients with cirrhosis and normal controls using 18F-FDG-PET/CT: a pilot study
Authors
Ana Hernandez-Martinez
Victor A. Marin-Oyaga
Ali Salavati
Babak Saboury
Ion Codreanu
Marnix G. E. H. Lam
Drew A. Torigian
Abass Alavi
Publication date
01-01-2014
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 1/2014
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-013-0780-y

Other articles of this Issue 1/2014

Annals of Nuclear Medicine 1/2014 Go to the issue

Technical note

An animal PET scanner using flat-panel position-sensitive PMTs

Original Article

p53 antibody: is it an indicator of dedifferentiated thyroid cancer?

Original Article

On the use of [18F]DOPA as an imaging biomarker for transplanted islet mass

Original Article

Value of fusion of PET and MRI in the detection of intra-pelvic recurrence of gynecological tumor: comparison with 18F-FDG contrast-enhanced PET/CT and pelvic MRI

Original Article

Visual and semi-quantitative analyses of dual-phase breast-specific gamma imaging with Tc-99m-sestamibi in detecting primary breast cancer

Original Article

Optimization of iterative reconstruction parameters with attenuation correction, scatter correction and resolution recovery in myocardial perfusion SPECT/CT